CY1115686T1 - Αναστολεις της δρασης της ακτ - Google Patents

Αναστολεις της δρασης της ακτ

Info

Publication number
CY1115686T1
CY1115686T1 CY20141100899T CY141100899T CY1115686T1 CY 1115686 T1 CY1115686 T1 CY 1115686T1 CY 20141100899 T CY20141100899 T CY 20141100899T CY 141100899 T CY141100899 T CY 141100899T CY 1115686 T1 CY1115686 T1 CY 1115686T1
Authority
CY
Cyprus
Prior art keywords
act
suspensions
serine
compounds
series
Prior art date
Application number
CY20141100899T
Other languages
Greek (el)
English (en)
Inventor
Lixin Zhang
Graham Peter Trevitt
Hughes Miel
Frank Burkamp
Timothy Harrison
Andrew John Wilkinson
Charles-Henry Fabritius
Original Assignee
Almac Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Limited filed Critical Almac Discovery Limited
Publication of CY1115686T1 publication Critical patent/CY1115686T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20141100899T 2009-12-23 2014-10-31 Αναστολεις της δρασης της ακτ CY1115686T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
EP10800980.4A EP2516435B8 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
CY1115686T1 true CY1115686T1 (el) 2017-01-25

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100899T CY1115686T1 (el) 2009-12-23 2014-10-31 Αναστολεις της δρασης της ακτ

Country Status (21)

Country Link
US (1) US9221838B2 (https=)
EP (1) EP2516435B8 (https=)
JP (1) JP5923043B2 (https=)
KR (1) KR20140015157A (https=)
CN (1) CN102791708B (https=)
AU (1) AU2010334591C1 (https=)
BR (1) BR112012015677A2 (https=)
CA (1) CA2783340C (https=)
CY (1) CY1115686T1 (https=)
DK (1) DK2516435T3 (https=)
ES (1) ES2503794T3 (https=)
GB (1) GB0922589D0 (https=)
IL (1) IL220153A (https=)
MX (1) MX2012007274A (https=)
NZ (1) NZ600453A (https=)
PL (1) PL2516435T3 (https=)
PT (1) PT2516435E (https=)
RU (1) RU2579513C2 (https=)
SG (1) SG181517A1 (https=)
SI (1) SI2516435T1 (https=)
WO (1) WO2011077098A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) * 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
JP6787899B2 (ja) * 2014-12-23 2020-11-18 ベルゲンビオ アーエスアー 医薬的活性化合物
US10323044B2 (en) * 2015-02-27 2019-06-18 Taiho Pharmaceutical Co., Ltd. Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
MA45865A (fr) * 2016-08-07 2021-04-14 Wistar Inst Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
UA125730C2 (uk) * 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) * 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2025250545A1 (en) * 2024-05-28 2025-12-04 Alterome Therapeutics, Inc. Akt1 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181893B1 (pl) * 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) * 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) * 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity

Also Published As

Publication number Publication date
JP5923043B2 (ja) 2016-05-24
SI2516435T1 (sl) 2014-12-31
RU2579513C2 (ru) 2016-04-10
ES2503794T3 (es) 2014-10-07
PL2516435T3 (pl) 2015-01-30
KR20140015157A (ko) 2014-02-06
MX2012007274A (es) 2012-10-03
AU2010334591B2 (en) 2014-04-10
GB0922589D0 (en) 2010-02-10
EP2516435B8 (en) 2014-10-15
AU2010334591C1 (en) 2014-07-31
IL220153A0 (en) 2012-07-31
BR112012015677A2 (pt) 2015-06-30
DK2516435T3 (da) 2014-10-13
EP2516435A1 (en) 2012-10-31
US9221838B2 (en) 2015-12-29
RU2012131115A (ru) 2014-01-27
HK1171013A1 (en) 2013-03-15
JP2013515710A (ja) 2013-05-09
US20130116243A1 (en) 2013-05-09
EP2516435B1 (en) 2014-08-06
CN102791708A (zh) 2012-11-21
IL220153A (en) 2015-05-31
NZ600453A (en) 2013-10-25
CA2783340C (en) 2015-11-24
CA2783340A1 (en) 2011-06-30
WO2011077098A1 (en) 2011-06-30
WO2011077098A9 (en) 2012-04-19
CN102791708B (zh) 2016-03-02
AU2010334591A1 (en) 2012-06-21
PT2516435E (pt) 2014-11-13
SG181517A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
CY1115686T1 (el) Αναστολεις της δρασης της ακτ
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
WO2011033265A8 (en) Pharmaceutical compounds
CY1112077T1 (el) Θεραπεια με πιρφενιδονη αποφευγοντας την φλουβοξαμινη
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
MX2013009873A (es) Inhibidores triciclicos de cinasas.
EP2331530B8 (en) Fused multicyclic compounds as protein kinase inhibitors
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ